Juneja Explores AI’s Impact in Early Cancer Detection and Treatment
In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.
In this episode of Targeted Talks, Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses the exciting advancements of artificial intelligence (AI) in 2024, specifically focusing on its transformative impact on early cancer detection.
AI is revolutionizing early detection, and according to Juneja, this is particularly true in challenging cancers like pancreatic and breast cancer. By analyzing medical images with unprecedented accuracy, AI has shown its ability to significantly enhance both sensitivity and specificity, leading to earlier diagnoses and improved patient outcomes.
AI is also moving beyond simple image analysis, now incorporating a multi-modal approach. Research has shown AI to consider a wide range of factors like age, gender, lifestyle habits, and even genetic predispositions to predict individual cancer risk more accurately. With such a personalized approach, AI allows for more proactive interventions and targeted prevention strategies.
“Artificial intelligence has really given us reason for hope when it comes to detection earlier in cancers, which obviously, the hope is that they get cured quicker,” says Juneja in the interview with Targeted OncologyTM.
Juneja also discusses how AI is revolutionizing treatment decisions. By analyzing complex tissue samples and patient data, AI can predict the likelihood of response to various therapies. This helps oncologists select the most effective treatment plan for each individual patient, maximizing treatment benefits and minimizing adverse events.
However, the integration of AI in cancer care also presents challenges, which Juneja addresses, including concerns such as the need for standardized data across institutions, and the potential for inherent biases in AI algorithms. Despite these challenges, Juneja emphasizes the immense potential of AI to improve the overall cancer care experience.
“These are all things that do not replace physicians by any means, or some of our diagnostic tests, but certainly leverage and maybe one day, logarithmically help the utility or use case for these imaging and molecular- or blood-based screenings that we do,” explains Juneja.
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
